A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644)

Phase 1 Unknown 18 enrolled International AIDS Vaccine Initiative AURUM Tembisa Clinical Research · collab Center for Family Health Research · collab ModernaTX, Inc. · collab

NaSingle-groupOpen-labelPrevention

Summary

A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) in HIV-1 Uninfected Adults in Good General Health.

Timeline

Start: 2022-05-25
Primary completion: 2023-06-30
Completion: 2023-06-30

Publications

Libera M, Caputo V, Laterza G, Moudoud L, Soggiu A, Bonizzi L, Diotti RA. The Question of HIV Vaccine: Why Is a Solution Not Yet Available? J Immunol Res. 2024 Apr 8;2024:2147912. doi: 10.1155/2024/2147912. eCollection 2024.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	mRNA-1644	Messenger RNA (mRNA)	100 ug	—

A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644)

Summary

Timeline

Publications

Drugs

Indications